JPWO2021151865A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021151865A5 JPWO2021151865A5 JP2022545799A JP2022545799A JPWO2021151865A5 JP WO2021151865 A5 JPWO2021151865 A5 JP WO2021151865A5 JP 2022545799 A JP2022545799 A JP 2022545799A JP 2022545799 A JP2022545799 A JP 2022545799A JP WO2021151865 A5 JPWO2021151865 A5 JP WO2021151865A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- optionally substituted
- different
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 150000003839 salts Chemical class 0.000 claims 30
- 239000012453 solvate Substances 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 150000004677 hydrates Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 208000030090 Acute Disease Diseases 0.000 claims 3
- 208000017667 Chronic Disease Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- VEQJOYXHKAGVOA-UHFFFAOYSA-N 2-(4-chloro-3-fluorophenoxy)-N-[1-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]piperidin-4-yl]acetamide Chemical compound ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)C=C1)F VEQJOYXHKAGVOA-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- BCOHCWNZKWCNLF-UHFFFAOYSA-N ClC1=C(C=C(C=N1)OCC(=O)NC1CCN(CC1)C=1OC(=NN=1)C1=CC=C(C=C1)Cl)F Chemical compound ClC1=C(C=C(C=N1)OCC(=O)NC1CCN(CC1)C=1OC(=NN=1)C1=CC=C(C=C1)Cl)F BCOHCWNZKWCNLF-UHFFFAOYSA-N 0.000 claims 1
- BPUQNFVPMJAHCF-UHFFFAOYSA-N ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)C2=NC=C(C=C2)Cl)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)C2=NC=C(C=C2)Cl)C=C1)F BPUQNFVPMJAHCF-UHFFFAOYSA-N 0.000 claims 1
- GWASECVAMQWICJ-UHFFFAOYSA-N ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)CCCC(F)(F)F)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)CCCC(F)(F)F)C=C1)F GWASECVAMQWICJ-UHFFFAOYSA-N 0.000 claims 1
- UFNPKMWXYWSEMU-UHFFFAOYSA-N ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)N2CC(C2)OC(F)(F)F)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)N2CC(C2)OC(F)(F)F)C=C1)F UFNPKMWXYWSEMU-UHFFFAOYSA-N 0.000 claims 1
- RNWGWNCGUWDDIK-UHFFFAOYSA-N ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)OCCOC(F)(F)F)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)NC2CCN(CC2)C=2OC(=NN=2)OCCOC(F)(F)F)C=C1)F RNWGWNCGUWDDIK-UHFFFAOYSA-N 0.000 claims 1
- MSGZFVNFCLNRMC-UHFFFAOYSA-N ClC1=C(C=C(OCC(=O)NC2CCN(CCC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)NC2CCN(CCC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)C=C1)F MSGZFVNFCLNRMC-UHFFFAOYSA-N 0.000 claims 1
- OZCNOJOQJRMKGF-UHFFFAOYSA-N ClC1=C(C=C(OCC(=O)NN2CCN(CC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)NN2CCN(CC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)C=C1)F OZCNOJOQJRMKGF-UHFFFAOYSA-N 0.000 claims 1
- BVKFSWSNFDQKAK-ROUUACIJSA-N ClC1=C(C=C(OCC(=O)N[C@@H]2[C@H](CN(CC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)O)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)N[C@@H]2[C@H](CN(CC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)O)C=C1)F BVKFSWSNFDQKAK-ROUUACIJSA-N 0.000 claims 1
- BVKFSWSNFDQKAK-QZTJIDSGSA-N ClC1=C(C=C(OCC(=O)N[C@H]2[C@@H](CN(CC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)O)C=C1)F Chemical compound ClC1=C(C=C(OCC(=O)N[C@H]2[C@@H](CN(CC2)C=2OC(=NN=2)C2=CC=C(C=C2)Cl)O)C=C1)F BVKFSWSNFDQKAK-QZTJIDSGSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims 1
- 201000006347 Intellectual Disability Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical group C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 230000003938 response to stress Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000000464 thioxo group Chemical group S=* 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20154031 | 2020-01-28 | ||
| EP20154031.7 | 2020-01-28 | ||
| PCT/EP2021/051697 WO2021151865A1 (en) | 2020-01-28 | 2021-01-26 | Modulators of the integrated stress response pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511616A JP2023511616A (ja) | 2023-03-20 |
| JPWO2021151865A5 true JPWO2021151865A5 (pt) | 2024-02-02 |
Family
ID=69374193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545799A Pending JP2023511616A (ja) | 2020-01-28 | 2021-01-26 | 統合的ストレス応答経路の調節因子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230125481A1 (pt) |
| EP (1) | EP4096665A1 (pt) |
| JP (1) | JP2023511616A (pt) |
| KR (1) | KR20220133252A (pt) |
| CN (1) | CN114980894A (pt) |
| AU (1) | AU2021213289A1 (pt) |
| BR (1) | BR112022012643A2 (pt) |
| CA (1) | CA3162526A1 (pt) |
| IL (1) | IL294805A (pt) |
| MX (1) | MX2022009243A (pt) |
| WO (1) | WO2021151865A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302219A (en) | 2020-10-22 | 2023-06-01 | Evotec Int Gmbh | Integrated stress response pathway modulators |
| WO2022084448A1 (en) | 2020-10-22 | 2022-04-28 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| US20230391725A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| WO2024109736A1 (zh) * | 2022-11-21 | 2024-05-30 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4033412A1 (de) | 1990-10-20 | 1992-04-23 | Bayer Ag | Fungizide mittel auf basis von heterocyclisch substituierten sulfonen |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| AU2014369053B2 (en) * | 2013-12-20 | 2019-03-14 | Institute For Drug Discovery, Llc | Substituted amino triazoles, and methods using same |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| RU2018146946A (ru) | 2016-06-08 | 2020-07-10 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения |
| WO2017212425A1 (en) | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CN110896634A (zh) | 2017-07-03 | 2020-03-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物 |
| JP2020525513A (ja) | 2017-07-03 | 2020-08-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌および他の疾患を治療するためのａｔｆ４阻害剤としてのｎ−（３−（２−（４−クロロフェノキシ）アセトアミドビシクロ［１．１．１］ペンタン−１−イル）−２−シクロブタン−１−カルボキサミド誘導体および関連化合物 |
| JP2020530446A (ja) | 2017-08-09 | 2020-10-22 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 化合物、組成物、及び、方法 |
| JP7382308B2 (ja) | 2017-09-01 | 2023-11-16 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物、及び、方法 |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| JP7335241B2 (ja) | 2017-11-02 | 2023-08-29 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| BR112020008827A2 (pt) | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | moduladores da via de estresse integrada |
| IL274406B2 (en) | 2017-11-02 | 2024-04-01 | Calico Life Sciences Llc | Combined pressure pathway modulators |
| BR112020008825A2 (pt) | 2017-11-02 | 2020-10-20 | Calico Life Sciences Llc | moduladores da via de estresse integrada |
| BR112020008834A2 (pt) | 2017-11-02 | 2020-12-22 | Calico Life Sciences Llc | Moduladores da via de estresse integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3704125A1 (en) | 2017-11-02 | 2020-09-09 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| EP3723762A4 (en) | 2017-12-13 | 2021-12-08 | Praxis Biotech LLC | STRESS INTEGRATED RESPONSE PATH INHIBITORS |
| EP3768660A1 (en) * | 2018-03-23 | 2021-01-27 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
-
2021
- 2021-01-26 JP JP2022545799A patent/JP2023511616A/ja active Pending
- 2021-01-26 MX MX2022009243A patent/MX2022009243A/es unknown
- 2021-01-26 US US17/759,490 patent/US20230125481A1/en active Pending
- 2021-01-26 BR BR112022012643A patent/BR112022012643A2/pt unknown
- 2021-01-26 IL IL294805A patent/IL294805A/en unknown
- 2021-01-26 KR KR1020227029412A patent/KR20220133252A/ko unknown
- 2021-01-26 CN CN202180011613.3A patent/CN114980894A/zh active Pending
- 2021-01-26 WO PCT/EP2021/051697 patent/WO2021151865A1/en unknown
- 2021-01-26 CA CA3162526A patent/CA3162526A1/en active Pending
- 2021-01-26 EP EP21702218.5A patent/EP4096665A1/en active Pending
- 2021-01-26 AU AU2021213289A patent/AU2021213289A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019077725A5 (pt) | ||
| JP2022096662A5 (pt) | ||
| JP2023156479A5 (pt) | ||
| JP2003510359A5 (pt) | ||
| JP2014511869A5 (pt) | ||
| WO2004089367A1 (en) | Pharmaceutical use of substituted 1,2,4-triazoles | |
| JP2005526723A5 (pt) | ||
| JP2020516671A5 (pt) | ||
| JP2014525444A5 (pt) | ||
| JP2015520752A5 (pt) | ||
| JP2010533158A5 (pt) | ||
| JP2009523165A5 (pt) | ||
| JP2010529991A5 (pt) | ||
| JP2006523627A5 (pt) | ||
| JP2014526501A5 (pt) | ||
| JP2007519754A5 (pt) | ||
| JP2004502670A5 (pt) | ||
| JP2013519680A5 (pt) | ||
| JP2008543781A5 (pt) | ||
| RU2003112610A (ru) | Производные пиразола для лечения вирксных заболеваний | |
| RU2006125446A (ru) | Производные n-замещенного n-сульфониламиноциклопропана и их фармацевтическое применение | |
| JP2004511469A5 (pt) | ||
| RU2006101541A (ru) | Производные пиперазина и способ их применения | |
| JP2018529744A5 (pt) | ||
| JP2011500679A5 (pt) |